White House COVID-19 response coordinator Jeff Zients warned Friday that the unvaccinated are "looking at a winter of severe illness and death -- for yourselves, your families and the hospitals you may soon overwhelm."

CDC director Rochelle Walensky said she expects omicron to become the dominant variant in the coming weeks.

Asked whether the CDC will change its guidance on vaccinated people quarantining after exposure, which they currently don't have to, Walensky said, "We are actively following the science in that area, with regard to how the viral burden is both among vaccinated people and unvaccinated people, and the natural history of that viral burden with regard to isolation."

"And as that science emerges, we will update our evidence if need be," she said.

-ABC News' Cheyenne Haslett

The United Kingdom reported 93,045 new cases in the last 24 hours, breaking a daily record for the third day in a row.

The total number of cases over the last week now stands at 477,229, a 38.6% increase from the previous week.

-ABC News' Guy Davies

Friday's four Radio City Rockettes shows have been canceled due to breakthrough COVID-19 cases in the New York City production.

Plans for future shows haven't been determined.

-ABC News' Aaron Katersky

The Centers for Disease Control and Prevention on Friday endorsed a practice in schools called “test-to-stay,” which allows unvaccinated kids and staff to test instead of quarantine after being exposed to COVID-19.

The CDC says the practice can be employed in addition to other mitigation measures, such as vaccination and at least 3-feet of physical distance among students wearing masks.

The new guidance follows two studies out of Los Angeles County, California, and Lake County, Illinois. Both studies found no significant transmission in school when test-to-stay was used.

The studies were conducted before the omicron variant was detected in the U.S.

-ABC News' Anne Flaherty

Pfizer's forthcoming COVID-19 treatment could be authorized for emergency use in the United States by the end of this year or early next year, pending the Food and Drug Administration's regulatory timeline, Pfizer CEO Albert Bourla told ABC News.

The pharmaceutical giant announced Tuesday that it has submitted promising new data to the FDA, including lab experiments showing its oral antiviral medicine, Paxlovid, will likely work against the omicron variant. And in updated clinical trial data, Pfizer found the treatment reduces the risk of being hospitalized or dying by 89% when taken within three days of being diagnosed with COVID-19, and 88% when taken within five days of being diagnosed among high-risk, unvaccinated patients.

"It is a game changer," Bourla told ABC News. "But at the same time, I want to emphasize that no one should use the existence of the pill as an excuse to avoid vaccination."

Bourla said the medicine could save thousands of lives.

"We did some calculations how many deaths or hospitalizations can be avoided based on the current U.S. mortality rates and the current U.S. hospitalization rates," he said. "On the back-of-the-envelope calculation, we estimate that 100,000 people if they take the pill, we will avoid 6,000 hospitalizations and 1,200 deaths approximately."

-ABC News' Sony Salzman